A Phase 3 Multi-Center, Placebo-Controlled, Double Blind, 3-Armed Parallel Group, Comparative Study of SPM 962 4.5 and 6.75 mg/Day to Investigate Superiority to Placebo in Patients With Restless Legs Syndrome.
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2017
At a glance
- Drugs Rotigotine (Primary)
- Indications Restless legs syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 21 Sep 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Sep 2011 Actual end date (Sep 2011) added as reported by ClinicalTrials.gov.
- 11 Mar 2010 New trial record